| Metric | Q3-26 | Q3-25 |
|---|---|---|
| Revenue | 8,300 | 7,769 |
| Pretax Income | 3,063 | 3,641 |
| Net Income | 2,429 | 3,052 |
| Diluted EPS | 1.94 | 2.43 |
- Net Income YoY
- -20.4%
Key highlights
- Total revenue reached $8,300 million in Q3-26, up from $7,769 million in Q3-25
- Net income declined 20.4% year-over-year to $2,429 million
- Diluted earnings per share fell to $1.94 from $2.43 in the prior year period
- Company recorded a year-to-date net loss of $6.05 billion due to $11.3 billion in IPR&D expenses
- Full-year 2026 product sales guidance raised to a range of $31,000 million to $31,300 million
How the Period Went
Gilead Sciences recorded total revenue of $8,300 million for the third quarter of 2026, representing a 6.8% increase over the $7,769 million reported in the same period last year. This growth was underpinned by $8,290 million in product sales, highlighting the company's strong commercial performance in its core therapeutic areas. However, bottom-line metrics experienced a contraction during the period. Net income fell to $2,429 million from $3,052 million in the prior year's third quarter, a year-over-year decrease of 20.4%. Diluted earnings per share similarly declined to $1.94, compared to $2.43 in Q3-2025, primarily reflecting higher operating costs and strategic pipeline investments that offset the top-line gains.
Margins and Profitability
Profitability in the third quarter was impacted by a shift in the cost structure, with pretax income decreasing to $3,063 million from $3,641 million a year ago. While the quarterly performance remained profitable, the company’s year-to-date results reflect a different financial reality. For the first nine months of 2026, Gilead reported a net loss of $6.05 billion. This significant deficit was driven by $11.3 billion in acquired in-process research and development expenses. These charges, related to strategic acquisitions and collaborations, are intended to bolster the long-term drug pipeline but have exerted substantial pressure on current-year GAAP profitability and operating margins.
Business Overview
Gilead Sciences is a biopharmaceutical company focused on developing medicines for life-threatening diseases, maintaining a dominant position in the HIV, viral hepatitis, and oncology markets. The company’s core segments revolve around antiviral therapies and an expanding portfolio in cell therapy. Markets served include global healthcare providers and government health programs. Gilead’s operational model emphasizes short commercial lead times, resulting in no material order backlog. According to investor reports from October 2026, the company recently raised its full-year 2026 product sales guidance to a range of $31,000 million to $31,300 million, signaling continued demand for its primary drug portfolio despite the heavy R&D expenditure cycle.
Financial Context and Industry Landscape
With a market capitalization of $205.35 billion, Gilead remains a heavyweight in the healthcare sector. The stock has shown momentum with a 23.99% gain over the last quarter and an RSI of 70.0. This performance comes amid a broader industry trend where major drug manufacturers are navigating R&D-heavy cycles to replace revenues from older, off-patent medications. Gilead’s upcoming milestones include FDA PDUFA target action dates for anito-cel in December 2026 and once-weekly Yeztugo in February 2027. These regulatory decisions are critical checkpoints for the company’s post-2026 revenue trajectory as it seeks to diversify away from legacy antiviral treatments into next-generation oncology and preventative therapies.
Up 1.2% since our story on 30 Oct: $165.61 when we broke it → $167.58 at the close on 16 Nov. Daily closing prices. Source: Yahoo Finance.
Show the prices
| 19 Oct | $153.07 |
|---|---|
| 20 Oct | $156.51 |
| 21 Oct | $153.57 |
| 22 Oct | $157.19 |
| 23 Oct | $156.04 |
| 26 Oct | $158.69 |
| 27 Oct | $159.08 |
| 28 Oct | $159.20 |
| 29 Oct | $165.61 |
| 30 Oct | $170.68 |
| 2 Nov | $170.33 |
| 3 Nov | $167.47 |
| 4 Nov | $174.48 |
| 5 Nov | $167.57 |
| 6 Nov | $166.89 |
| 9 Nov | $169.32 |
| 10 Nov | $170.87 |
| 11 Nov | $169.73 |
| 12 Nov | $167.95 |
| 13 Nov | $168.08 |
| 16 Nov | $167.58 |
Sector Dynamics
- Global demand for specialized HIV and oncology therapies remains robust despite macroeconomic volatility
- Industry-wide focus on biologic cliffs is driving increased capital allocation toward in-process R&D
- Regulatory scrutiny on PDUFA dates for cell therapy products is intensifying across the healthcare sector
- Peers like AbbVie and Merck are similarly balancing high acquisition costs with the need for new revenue streams
- Healthcare equity performance has been bolstered by favorable regulatory outlooks for next-generation antiviral treatments
| Date | Announcement | Amount |
|---|---|---|
| 29 Oct 2026 | Q3 2026 financial results and FY 2026 guidanceSource: investors.gilead.com | $8.30 Billion |
| 04 Aug 2026 | Q2 2026 financial results and FY 2026 guidanceSource: investors.gilead.com | $7.80 Billion |
| 07 May 2026 | Q1 2026 financial results and FY 2026 guidanceSource: SEC filing | $6.96 Billion |
| 10 Feb 2026 | Q4 2025 financial results and FY 2026 guidanceSource: SEC filing | $7.92 Billion |
| 30 Oct 2025 | Q3 2025 financial results and FY 2025 guidanceSource: gilead.com | $7.77 Billion |
| 07 Aug 2025 | Q2 2025 financial results and FY 2025 guidanceSource: SEC filing | $7.08 Billion |
| Share price | $165.61 |
|---|---|
| Market cap | $205.3B |
| Revenue (annual) | $29.4B |
| 1-month price change | +9.47% |
| Sector | HealthcareDrug Manufacturers - General |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
SEC filing by Gilead Sciences, Inc. announcing third quarter 2026 financial results.
Track GILEAD SCIENCES, INC. live
Get the next GILEAD SCIENCES, INC. SEC filing seconds after it lands.



